CX11
Code VCT220
Corxel Pharmaceuticals licensed this oral GLP 1 agonist from Vincentage Pharma in 2024. US phase 2 weight loss reached 11.5 percent at 36 weeks; a global phase 3 is planned for 2027.
CX11 comes from Corxel Pharmaceuticals and sits in the Incretins class on the board. Route: daily pill. Use tracked here: Obesity and overweight; type 2 diabetes in phase 2. It stands at Phase 2 on the board, with 1 news move logged; the latest is dated 27 Oct 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Here now
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Corxel Pharmaceuticalswith Vincentage Pharma
- Mechanism
- Small molecule agonist of the GLP 1 receptor
- Given as
- daily pill
- Lead use on the board
- Obesity and overweight; type 2 diabetes in phase 2
- Moves logged
- 1latest 6 days ago
CX11 news moves
-
Corxel CX11 heads for phase 3 as an Amanat SPAC merger brings about 377 million dollars
Corxel Pharmaceuticals will go public through Amanat Acquisition Corp to fund a global phase 3 trial of its daily GLP 1 pill. Phase 2 weight loss reached 11.5 percent at 36 weeks, and tolerability is the claim the trial must prove.
Other incretins molecules on the board, with their current stage.